INCY - Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison | Benzinga
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythaemia), in adults with anemia.
William Blair notes four JAK inhibitors approved for myelofibrosis - Incyte Corporation's (NASDAQ: INCY) (Outperform rating reiterated) Jakafi, Bristol-Myers Squibb Co's (NYSE: BMY) Inrebic, CTI BioPharma Corp's Vonjo, and Ojjaara.
None of the labeled indications require prior JAK inhibitor therapy, even though clinical ...